31 August 2022
Antibodies | Top 10 Cited Articles in 2021
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
1. “Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease”
by Irina A. Pashnina et al.
Antibodies 2021, 10(1), 9; https://doi.org/10.3390/antib10010009
Available online: https://www.mdpi.com/2073-4468/10/1/9
2. “Utilizing Immunocytokines for Cancer Therapy”
by Erin Runbeck et al.
Antibodies 2021, 10(1), 10; https://doi.org/10.3390/antib10010010
Available online: https://www.mdpi.com/2073-4468/10/1/10
3. “Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics”
by Xiaotian Zhong et al.
Antibodies 2021, 10(2), 13; https://doi.org/10.3390/antib10020013
Available online: https://www.mdpi.com/2073-4468/10/2/13
4. “From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry”
by Darja Kanduc
Antibodies 2021, 10(4), 36; https://doi.org/10.3390/antib10040036
Available online: https://www.mdpi.com/2073-4468/10/4/36
5. “Introduction to Antibody-Drug Conjugates.”
by Mark C. Pettinato
Antibodies 2021, 10(4), 42; https://doi.org/10.3390/antib10040042
Available online: https://www.mdpi.com/2073-4468/10/4/42
6. “Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets”
by Lokesh Agrawal et al.
Antibodies 2021, 10(1), 3; https://doi.org/10.3390/antib10010003
Available online: https://www.mdpi.com/2073-4468/10/1/3
7. “HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1”
by Marius Gramlich et al.
Antibodies 2021, 10(1), 11; https://doi.org/10.3390/antib10010011
Available online: https://www.mdpi.com/2073-4468/10/1/11
8. “Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer”
by Violet Y. Tu et al.
Antibodies 2021, 10(3), 25; https://doi.org/10.3390/antib10030025
Available online: https://www.mdpi.com/2073-4468/10/3/25
9. “An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer”
by Fazrena Nadia Md Akhir et al.
Antibodies 2021, 10(1), 2; https://doi.org/10.3390/antib10010002
Available online: https://www.mdpi.com/2073-4468/10/1/2
10. “Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy”
by Yasmin Jenkins et al.
Antibodies 2021, 10(2), 17; https://doi.org/10.3390/antib10020017
Available online: https://www.mdpi.com/2073-4468/10/2/17